With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ...
Hosted on MSN
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection
Capricor plans to resubmit its Duchenne therapy application in 2026 with new cardiac efficacy data. FDA signaled flexibility that could speed approval if results are strong. Retail traders called the ...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan.
B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data support a higher probability of Deramiocel approval, ...
The Phase 3 trial met its primary and secondary endpoints. Management anticipates approval in 2026, with highly lucrative milestone payments expected to follow in the years to come. 10 stocks we like ...
Taking advantage of investor interest in its Duchenne muscular dystrophy drug, Capricor Therapeutics secured an upsized US$150m late on Thursday from an overnight stock sale. Following an earlier wall ...
SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR), Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results